Safety and Efficacy of HB-1 for Panic Disorder

This is a multicenter, randomized, double-blind, placebo-controlled trial. All patients with panic disorder, with or without specified co-morbidities, who meet all of the inclusion and none of the exclusion criteria will be eligible. Patients and researchers will be blinded to their treatment group. The study will enroll approximately 80 adult patients who meet the diagnosis of panic disorder. The patients will be treated for 12 weeks including a 1 week safety follow up visit following the last dose of study drug.